<p>Agios Pharmaceuticals, Inc.（納斯達克代碼：AGIO - 獲取免費報告）在週三市場開盤前股價跳漲，此前公司發佈了超出預期的財報。該股票此前收於 24.80 美元，但開盤時為 26.50 美元。Agios Pharmaceuticals 的股票最後交易價格為 27.3740 美元，成交量為 437,023 股。</p>
<p>獲取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
<p>這家生物製藥公司報告本季度每股收益為（$1.69），超出分析師一致預期的（$1.82）0.13 美元。該公司本季度的收入為 2075 萬美元，而分析師預期為 1391 萬美元。Agios Pharmaceuticals 的淨利潤率為負 764.01%，股本回報率為負 31.07%。與去年同期相比，該公司的季度收入增長了 137.7%。</p>
<h2>分析師設定新目標價</h2>
<p>多家股票研究分析師最近對 AGIO 股票發表了看法。華爾街 Zen 在 3 月 22 日的報告中將 Agios Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。花旗集團在 3 月 5 日的報告中將 Agios Pharmaceuticals 的目標價從 38.00 美元上調至 46.00 美元，並給予該公司 “買入” 評級。摩根大通在 4 月 6 日的報告中將 Agios Pharmaceuticals 的目標價從 31.00 美元上調至 36.00 美元，並給予該公司 “中性” 評級。Weiss Ratings 在 3 月 27 日的報告中重新發布了對 Agios Pharmaceuticals 的 “賣出（d）” 評級。最後，HC Wainwright 在 4 月 20 日的報告中將 Agios Pharmaceuticals 的目標價從 65.00 美元下調至 50.00 美元，並對該股票設定了 “買入” 評級。六位投資分析師對該股票給予了 “買入” 評級，四位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 41.78 美元。</p>
<p><strong>閲讀我們對 AGIO 的最新分析</strong></p>
<h2>內部人士下注</h2>
<p>在其他新聞中，內部人士 James William Burns 在 4 月 2 日的交易中出售了 3280 股公司的股票。股票以平均價格 34.71 美元出售，總價值為 113,848.80 美元。出售後，該內部人士直接持有 49,306 股公司股票，價值為 1,711,411.26 美元。這代表其持股減少了 6.24%。該交易已在與證券交易委員會的法律文件中披露，文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。此外，內部人士 Sarah Gheuens 在 4 月 2 日的交易中出售了 2940 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 102,047.40 美元。出售完成後，該內部人士在公司中持有 80,277 股，價值約為 2,786,414.67 美元。這代表其持股減少了 3.53%。該交易的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。在過去三個月中，內部人士出售了價值 520,405 美元的 15,582 股公司股票。公司內部人士持有公司股票的 4.93%。</p>
<h2>機構投資者對 Agios Pharmaceuticals 的看法</h2>
<p>幾家對沖基金最近買入和賣出了 AGIO 的股票。AQR Capital Management LLC 在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 66.8%。AQR Capital Management LLC 現在持有 51,489 股該生物製藥公司的股票，價值為 1,498,000 美元，此前在上一季度購買了額外的 20,625 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 7.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在持有 43,327 股該生物製藥公司的股票，價值為 1,274,000 美元，此前在上一季度購買了額外的 2,920 股。NewEdge Advisors LLC 在第一季度購買了 Agios Pharmaceuticals 的新股份，價值約為 40,000 美元。高盛集團在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 16.1%。高盛集團現在持有 658,652 股該生物製藥公司的股票，價值為 19,299,000 美元，此前在上一季度購買了額外的 91,482 股。最後，Woodline Partners LP 在第一季度購買了 Agios Pharmaceuticals 的新股份，價值約為 597,000 美元。</p>
<h2>Agios Pharmaceuticals 股價上漲 11.0%</h2>
<p>該公司 50 日簡單移動平均線為 29.87 美元，200 日簡單移動平均線為 31.07 美元。該公司的市值為 16.4 億美元，市盈率為-3.86，貝塔值為 0.79。</p>
<h2>Agios Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Agios Pharmaceuticals, Inc 是一家生物製藥公司，成立於 2008 年，源於 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司總部位於馬薩諸塞州劍橋，Agios 專注於理解和針對細胞代謝，以開發針對癌症和罕見遺傳疾病的新療法。該公司的科學平台整合了基因組發現、代謝分析和精準醫學方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
<p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Agios Pharmaceuticals 更好</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Agios Pharmaceuticals 嗎？</h2>
<p>在考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Agios Pharmaceuticals 並不在名單上。</p>
<p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Agios制藥

<p>Agios 製藥（NASDAQ:AGIO）股價飆升至 26.50 美元，此前報告的每股收益為（1.69 美元），超出預期的（1.82 美元）。收入達到 2075 萬美元，超過了 1391 萬美元的預測。分析師的評級不一，六位分析師推薦買入，四位分析師建議持有。內部交易中出現了大量銷售以覆蓋税務義務。機構投資者增加了持股比例，AQR 資本管理公司將其持倉提高了 66.8%。該股票的市值為 16.4 億美元，交易上漲 11.0%</p>

<p>Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) shares gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $24.80, but opened at $26.50. Agios Pharmaceuticals shares last traded at $27.3740, with a volume of 437,023 shares traded.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc.（納斯達克代碼：AGIO - 獲取免費報告）在週三市場開盤前股價跳漲，此前公司發佈了超出預期的財報。該股票此前收於 24.80 美元，但開盤時為 26.50 美元。Agios Pharmaceuticals 的股票最後交易價格為 27.3740 美元，成交量為 437,023 股。</p>
</div><p>Get <strong>Agios Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Agios Pharmaceuticals</strong> 的提醒：</p>
</div><p>The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts' consensus estimates of ($1.82) by $0.13. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.91 million. Agios Pharmaceuticals had a negative net margin of 764.01% and a negative return on equity of 31.07%. The firm's revenue for the quarter was up 137.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>這家生物製藥公司報告本季度每股收益為（$1.69），超出分析師一致預期的（$1.82）0.13 美元。該公司本季度的收入為 2075 萬美元，而分析師預期為 1391 萬美元。Agios Pharmaceuticals 的淨利潤率為負 764.01%，股本回報率為負 31.07%。與去年同期相比，該公司的季度收入增長了 137.7%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of equities research analysts have recently weighed in on AGIO shares. Wall Street Zen raised shares of Agios Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, March 22nd. Citigroup boosted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, March 5th. JPMorgan Chase &amp; Co. boosted their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a &#34;neutral&#34; rating in a report on Monday, April 6th. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th. Finally, HC Wainwright dropped their price objective on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of &#34;Hold&#34; and a consensus target price of $41.78.</p>
<div class="lb-trans"><p>多家股票研究分析師最近對 AGIO 股票發表了看法。華爾街 Zen 在 3 月 22 日的報告中將 Agios Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。花旗集團在 3 月 5 日的報告中將 Agios Pharmaceuticals 的目標價從 38.00 美元上調至 46.00 美元，並給予該公司 “買入” 評級。摩根大通在 4 月 6 日的報告中將 Agios Pharmaceuticals 的目標價從 31.00 美元上調至 36.00 美元，並給予該公司 “中性” 評級。Weiss Ratings 在 3 月 27 日的報告中重新發布了對 Agios Pharmaceuticals 的 “賣出（d）” 評級。最後，HC Wainwright 在 4 月 20 日的報告中將 Agios Pharmaceuticals 的目標價從 65.00 美元下調至 50.00 美元，並對該股票設定了 “買入” 評級。六位投資分析師對該股票給予了 “買入” 評級，四位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 41.78 美元。</p>
</div><p><strong>Read Our Latest Analysis on AGIO</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 AGIO 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, insider James William Burns sold 3,280 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $113,848.80. Following the sale, the insider directly owned 49,306 shares of the company's stock, valued at $1,711,411.26. This represents a 6.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $102,047.40. Following the completion of the sale, the insider owned 80,277 shares in the company, valued at approximately $2,786,414.67. This represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 15,582 shares of company stock worth $520,405. Company insiders own 4.93% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 James William Burns 在 4 月 2 日的交易中出售了 3280 股公司的股票。股票以平均價格 34.71 美元出售，總價值為 113,848.80 美元。出售後，該內部人士直接持有 49,306 股公司股票，價值為 1,711,411.26 美元。這代表其持股減少了 6.24%。該交易已在與證券交易委員會的法律文件中披露，文件可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。此外，內部人士 Sarah Gheuens 在 4 月 2 日的交易中出售了 2940 股公司的股票。該股票以平均價格 34.71 美元出售，總價值為 102,047.40 美元。出售完成後，該內部人士在公司中持有 80,277 股，價值約為 2,786,414.67 美元。這代表其持股減少了 3.53%。該交易的披露信息可在 SEC 文件中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。出售是為了覆蓋與股權獎勵歸屬相關的税收扣繳義務。在過去三個月中，內部人士出售了價值 520,405 美元的 15,582 股公司股票。公司內部人士持有公司股票的 4.93%。</p>
</div><h2>Institutional Investors Weigh In On Agios Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Agios Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds have recently bought and sold shares of AGIO. AQR Capital Management LLC boosted its position in Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after purchasing an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock worth $1,274,000 after purchasing an additional 2,920 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $40,000. Goldman Sachs Group Inc. boosted its position in Agios Pharmaceuticals by 16.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock worth $19,299,000 after purchasing an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $597,000.</p>
<div class="lb-trans"><p>幾家對沖基金最近買入和賣出了 AGIO 的股票。AQR Capital Management LLC 在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 66.8%。AQR Capital Management LLC 現在持有 51,489 股該生物製藥公司的股票，價值為 1,498,000 美元，此前在上一季度購買了額外的 20,625 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 7.2%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在持有 43,327 股該生物製藥公司的股票，價值為 1,274,000 美元，此前在上一季度購買了額外的 2,920 股。NewEdge Advisors LLC 在第一季度購買了 Agios Pharmaceuticals 的新股份，價值約為 40,000 美元。高盛集團在第一季度將其在 Agios Pharmaceuticals 的持倉增加了 16.1%。高盛集團現在持有 658,652 股該生物製藥公司的股票，價值為 19,299,000 美元，此前在上一季度購買了額外的 91,482 股。最後，Woodline Partners LP 在第一季度購買了 Agios Pharmaceuticals 的新股份，價值約為 597,000 美元。</p>
</div><h2>Agios Pharmaceuticals Trading Up 11.0%</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 股價上漲 11.0%</h2>
</div><p>The company has a 50-day simple moving average of $29.87 and a 200 day simple moving average of $31.07. The firm has a market cap of $1.64 billion, a PE ratio of -3.86 and a beta of 0.79.</p>
<div class="lb-trans"><p>該公司 50 日簡單移動平均線為 29.87 美元，200 日簡單移動平均線為 31.07 美元。該公司的市值為 16.4 億美元，市盈率為-3.86，貝塔值為 0.79。</p>
</div><h2>Agios Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Agios Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.</p>
<div class="lb-trans"><p>Agios Pharmaceuticals, Inc 是一家生物製藥公司，成立於 2008 年，源於 Dana-Farber 癌症研究所和 Broad Institute 的研究。公司總部位於馬薩諸塞州劍橋，Agios 專注於理解和針對細胞代謝，以開發針對癌症和罕見遺傳疾病的新療法。該公司的科學平台整合了基因組發現、代謝分析和精準醫學方法，以識別和推進能夠糾正或利用代謝功能障礙的小分子候選藥物。</p>
</div><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p>
<div class="lb-trans"><p>Agios 的主要產品是針對特定癌症突變的 IDH（異檸檬酸脱氫酶）抑制劑。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Agios Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Agios Pharmaceuticals 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Agios Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Agios Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Agios Pharmaceuticals 並不在名單上。</p>
</div><p>While Agios Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Agios Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Agios 製藥（NASDAQ:AGIO）股價因盈利超預期而跳空高開